Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men

27 oktober 2026 uppdaterad av: Lambda Surgical, Inc

This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.

The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.

LambdaGuide measurements will not be used to guide or modify clinical care.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.

The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.

Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.

During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.

For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.

Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.

Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.

The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.

Studietyp

Observationell

Inskrivning (Beräknad)

10

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02111
        • Rekrytering
        • PINE (Prostate Institution of New England)
        • Kontakt:
        • Huvudutredare:
          • Louis Liou, MD, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

22 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Manlig

Testmetod

Icke-sannolikhetsprov

Studera befolkning

No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.

Beskrivning

Inclusion Criteria:

  1. Adult male subject (22 years of age or older).
  2. Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
  3. Able and willing to provide informed consent before study participation.
  4. Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
  5. Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
  6. Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.

Exclusion Criteria:

  1. Participation is expected to interfere with or materially delay standard clinical care.
  2. Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
  3. Inability to provide informed consent.
  4. Inability to use the required compatible cystoscope or approved study configuration.
  5. Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: CASE_ONLY
  • Tidsperspektiv: PROSPECTIVE

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Clinical measurement feasibility
Tidsram: Procedure duration

Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained.

Procedure duration
Primary safety endpoint
Tidsram: From procedure date to 30 days after (+/-5 days)

Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events.

From procedure date to 30 days after (+/-5 days)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Calibration success
Tidsram: During Procedure

Calibration success

During Procedure
Camera deployment and expected image display
Tidsram: During Procedure

Camera deployment and expected image display

During Procedure
Spatial capture success
Tidsram: During Procedure

Spatial capture success

During Procedure
Valid point-selection success
Tidsram: During Procedure

Valid point-selection success

During Procedure
Successful measurement completion
Tidsram: During Procedure

Successful measurement completion

During Procedure
Calibration and measurement time
Tidsram: During Procedure

Calibration and measurement time (descriptive only)

During Procedure
Procedure interference
Tidsram: During Procedure

Procedure interference

During Procedure
User acceptance
Tidsram: During Procedure

User acceptance - based on Investigator Questionnaire

During Procedure
Observational comparative measurements (
Tidsram: During Procedure

Observational comparative measurements (descriptive only)

During Procedure

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Louis Liou, MD, PhD, PINE - Prostate Institution of New England

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 oktober 2027

Avslutad studie (Beräknad)

1 oktober 2027

Studieregistreringsdatum

Först inskickad

27 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

27 oktober 2026

Första postat (Faktisk)

3 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

27 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera